Newsletter 122 – Chikungunya: vaccine developed in partnership with Butantan induced protective antibody titers in 98.5% of study participants
Immunizer tested in 4,115 people generated neutralizing antibodies in 98.5% of the volunteers 28 days after the application of the single dose
14/09/2021Immunizer tested in 4,115 people generated neutralizing antibodies in 98.5% of the volunteers 28 days after the application of the single dose
